Genprex (NASDAQ:GNPX) Trading Up 0.9% – Should You Buy?

Genprex (NASDAQ:GNPX) shares rose 0.9% during trading on Monday . The stock traded as high as $3.65 and last traded at $3.48. Approximately 116,474 shares traded hands during mid-day trading, an increase of 143% from the average daily volume of 47,903 shares. The stock had previously closed at $3.45.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Genprex in a research note on Friday, July 17th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has a consensus rating of “Sell”.

Genprex Trading Up 0.9%

The stock has a market capitalization of $2.85 million, a price-to-earnings ratio of -0.03 and a beta of -0.94. The stock has a 50-day simple moving average of $5.01 and a 200 day simple moving average of $17.13.

Genprex (NASDAQ:GNPX) last issued its earnings results on Friday, August 14th. The company reported ($9.40) earnings per share for the quarter.

Institutional Investors Weigh In On Genprex

An institutional investor recently bought a new stake in Genprex stock. Manchester Financial Inc. acquired a new position in Genprex (NASDAQ:GNPX) in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 20,000 shares of the company’s stock, valued at approximately $36,000. Manchester Financial Inc. owned 0.22% of Genprex as of its most recent SEC filing. Institutional investors and hedge funds own 14.05% of the company’s stock.

About Genprex

Genprex, Inc is a clinical-stage biotechnology company focused on developing gene therapies for cancer and other serious diseases. The company’s technology is designed to deliver therapeutic genes into cells using a nonviral delivery system, with the goal of restoring tumor-suppressor activity or producing other disease-fighting effects.

Genprex’s lead product candidate is REQORSA® Immunogene Therapy (quaratusugene ozeplasmid), an investigational gene therapy being developed primarily for non-small cell lung cancer.